Adagene Inc. Files 6-K, Presents New Research Insights

Ticker: ADAG · Form: 6-K · Filed: 2024-11-07T00:00:00.000Z

Sentiment: neutral

Topics: 6-K, research, press-release

TL;DR

Adagene dropped a 6-K with new research posters – check the details.

AI Summary

Adagene Inc. filed a Form 6-K on November 7, 2024, reporting on its activities for the month of November 2024. The filing includes a press release titled "Adagene Presents Two Posters with New Insight," indicating the company shared new research findings. The report is filed under the Securities Exchange Act of 1934, with Peter Luo, Chief Executive Officer, signing on behalf of the company.

Why It Matters

This filing provides an update on Adagene's research and development activities, potentially impacting investor understanding of the company's progress in the pharmaceutical sector.

Risk Assessment

Risk Level: low — This filing is a routine report of foreign private issuer activities and does not contain significant financial or operational changes.

Key Players & Entities

FAQ

What is the main purpose of this Form 6-K filing?

The Form 6-K is a report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of November 2024.

What specific information is included in Exhibit 99.1?

Exhibit 99.1 is a press release titled "Adagene Presents Two Posters with New Insight."

Who signed the report on behalf of Adagene Inc.?

Peter Luo, Chief Executive Officer, signed the report on behalf of Adagene Inc.

What is Adagene Inc.'s principal executive office address?

Adagene Inc.'s principal executive office is located at 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, 215123, People's Republic of China.

Under which act is this report filed?

This report is filed under the Securities Exchange Act of 1934.

From the Filing

0001104659-24-115134.txt : 20241107 0001104659-24-115134.hdr.sgml : 20241107 20241107101024 ACCESSION NUMBER: 0001104659-24-115134 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20241107 FILED AS OF DATE: 20241107 DATE AS OF CHANGE: 20241107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adagene Inc. CENTRAL INDEX KEY: 0001818838 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39997 FILM NUMBER: 241433689 BUSINESS ADDRESS: STREET 1: 4F, BUILDING C14, NO. 218, XINGHU STREET STREET 2: SUZHOU INDUSTRIAL PARK CITY: JIANGSU STATE: F4 ZIP: 00000 BUSINESS PHONE: 86-512-87773632 MAIL ADDRESS: STREET 1: 4F, BUILDING C14, NO. 218, XINGHU STREET STREET 2: SUZHOU INDUSTRIAL PARK CITY: JIANGSU STATE: F4 ZIP: 00000 6-K 1 tm2427764d1_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a- 16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-39997 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s Republic of China +86-512-8777-3632 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F ¨ SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Adagene Inc. By: /s/ Peter Luo Name: Peter Luo Title: Chief Executive Officer Date: November 7, 2024 EXHIBIT INDEX Exhibit Description 99.1 Press release tilted “Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.” EX-99.1 2 tm2427764d1_99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade - - Clinical data show benefit of combining immune checkpoint inhibitors in MSS CRC and essential role of CTLA-4 to prime PD-L1 pathway - - Clinical poster selected by SITC as a ‘Top 100’ abstract out of 1439 regular abstracts - SAN DIEGO and SUZHOU, China, Nov. 7, 2024-- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced data at the SITC 39 th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024. The two poster presentations provide new insights on the increased therapeutic index (TI) for ADG126 and reinforce its clinical safety and efficacy profiles in combination with pembrolizumab* including in advanced Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). “CTLA-4 has an essential role in harnessing the immune system to improve outcomes for patients with cold and PD-L1 low or negative tumors, and CTLA-4 inhibition has been shown to prime T cells contributing to enhanced combination therapy activity,” said Daneng Li, MD, Associate Professor in the Department of Medical Onco

View on Read The Filing